Navigation Links
Jazz Pharmaceuticals To Report 2012 Fourth Quarter And Full Year Financial Results On February 26, 2013
Date:2/11/2013

DUBLIN, Feb. 11, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will host a conference call and live webcast on Tuesday, February 26, 2013 at 4:30 p.m. EST/9:30 p.m. GMT.  During the call, company management will provide a business and financial update and review its 2012 fourth quarter and full year financial results.

A live webcast of the presentation may be accessed from the Investors & Media section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

Investors may participate in the conference call by dialing +1 800-920-8624 in the U.S., or +1 617-597-5430 outside the U.S., and entering passcode 75109778.

A replay of the conference call will be available through March 5, 2013 by dialing +1 888-286-8010 in the U.S., or +1 617-801-6888 outside the U.S., and entering passcode 53780559.

An archived version of the webcast will be available for at least one week on the Investors section of the company's website at www.jazzpharmaceuticals.com.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion, Luvox CR® (fluvoxamine maleate), FazaClo® (clozapine, USP) HD and FazaClo LD. Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its international division, EUSA Pharma. For further information, see www.jazzpharmaceuticals.com.

 

 


'/>"/>
SOURCE Jazz Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... DURHAM, N.C. , Feb. 8, 2016  Avista ... appointed Eric Setzer as Chief Financial Officer (CFO). ... over twenty years of experience in various roles within ... Avista Pharma, he served as the Executive Director of ... organization in Raleigh, NC . Previously, ...
(Date:2/8/2016)...  HemaFlo Therapeutics, Inc. announced today that the United States ... 9,119,880 covering the use of NephroFlow to treat acute kidney ... founder, said, "We are pleased to secure our rights to ... , PhD, HemaFlo,s founder, said, "We are pleased to secure ... Dale Peterson , PhD, HemaFlo,s founder, said, "We ...
(Date:2/8/2016)... 2016 Palatin Technologies, Inc. (NYSE MKT: ... therapeutics for the treatment of diseases with significant ... that the United States Patent and Trademark Office ... U.S. Patent Application Serial Number 14/313,258 (the ,258 ... treating female sexual dysfunction using the formulation and ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth ... incidence rate of type 2 diabetes in the GrassrootsHealth cohort with substantially higher ... make a change in public health,” states Carole Baggerly, Director of GrassrootsHealth, “the ...
(Date:2/8/2016)... Las Vegas, Nevada (PRWEB) , ... February 08, ... ... Co-Founder at RowdMap, Inc., will be speaking on how healthcare companies can use ... project costs, manage the health of a population and intervene and capture the ...
(Date:2/8/2016)... ... February 08, 2016 , ... According to research by ... require dental technicians to be certified or obtain continuing education. To increase patient ... “What’s In Your Mouth?” campaign to inform dentists and patients about the possible ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... MyDecision™ empowers employers and organizations with the tools and information to lower the ... elements to cut the cost of providing employee healthcare benefits by as much ...
(Date:2/6/2016)... ... ... US Sports Camps is proud to sponsor the Bay Area Disc Association's ... leaders, ultimate organizations, and coaches from around the US. The theme for this year’s ... of Youth and Education, describes this year YUCC as “an important conversation we must ...
Breaking Medicine News(10 mins):